OpenAI has introduced the GPT-Rosalind drug discovery model, a new AI system designed to support biology, drug discovery, genomics, and broader life sciences research. The company says the model is built for complex scientific workflows and is intended to help researchers move faster through difficult, multi-step tasks.
Named after Rosalind Franklin, the scientist whose work was crucial to understanding DNA, the model reflects OpenAI’s growing push into science and medicine. According to the official announcement, GPT-Rosalind is designed to reason across molecules, proteins, genes, pathways, and disease biology.
OpenAI says GPT-Rosalind is optimised for literature review, evidence synthesis, genomics analysis, hypothesis generation, experimental planning, and interpreting research data. The goal is not simply to automate existing work, but to help scientists explore more possibilities and spot connections they might otherwise miss. The company has framed the model as part of a longer-term effort to build AI systems that can contribute to scientific discovery in areas with broad social impact.
GPT-Rosalind is not a general public release. OpenAI says it is currently available as a research preview for qualified customers through a trusted access program, including use in ChatGPT, Codex, and the API. OpenAI’s help documentation says access is limited to select institutions with service agreements, and that governance, biosafety, security controls, and intended use cases are part of the review process. That makes GPT-Rosalind a controlled rollout rather than a broadly open consumer product.
OpenAI life sciences partners
OpenAI says it is already working with companies and research organisations, including Amgen, Moderna, the Allen Institute, and Thermo Fisher Scientific. The company also highlights a broader life sciences push, including work with pharmaceutical and research partners to speed up discovery workflows. That partner list matters because it shows OpenAI is positioning the model for real-world scientific use, not just internal experimentation.
Drug discovery and biological research often involve fragmented data, long timelines, and complex decisions across many tools and sources. OpenAI argues that advanced AI can reduce that friction by helping researchers analyse evidence faster and design better next steps. For now, GPT-Rosalind appears to be an early but significant step in OpenAI’s effort to build domain-specific AI for science. Its success will likely be judged by whether it can deliver useful results in tightly controlled, high-stakes research environments.
